MedPath

Auryxia

These highlights do not include all the information needed to use AURYXIA safely and effectively. See full prescribing information for AURYXIA. AURYXIA (ferric citrate) tablets, for oral use Initial U.S. Approval: 2014

Approved
Approval ID

aadd18e0-3752-11e4-8510-0800200c9a66

Product Type

HUMAN PRESCRIPTION DRUG LABEL

Effective Date

Jan 22, 2024

Manufacturers
FDA

Akebia Therapeutics, Inc.

DUNS: 809557593

Products 1

Detailed information about drug products covered under this FDA approval, including NDC codes, dosage forms, ingredients, and administration routes.

ferric citrate

PRODUCT DETAILS

NDC Product Code59922-631
Application NumberNDA205874
Marketing CategoryC73594
Route of AdministrationORAL
Effective DateMarch 18, 2021
Generic Nameferric citrate

INGREDIENTS (1)

TETRAFERRIC TRICITRATE DECAHYDRATEActive
Quantity: 210 mg in 1 1
Code: Q91187K011
Classification: ACTIM
© Copyright 2025. All Rights Reserved by MedPath
Auryxia - FDA Approval | MedPath